Targeting Bruton's tyrosine kinase in B cell malignancies

RW Hendriks, S Yuvaraj, LP Kil - Nature Reviews Cancer, 2014 - nature.com
Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and
functions as an important regulator of cell proliferation and cell survival in various B cell …

Toll-like receptors signaling: A complex network for NF-κB activation in B-cell lymphoid malignancies

S Ntoufa, MG Vilia, K Stamatopoulos, P Ghia… - Seminars in cancer …, 2016 - Elsevier
Malignancies of mature B cells are quite distinctive in originating from well-differentiated
cells. Hence, it is not paradoxical that, similar to their normal counterparts, most mature B …

[HTML][HTML] B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3

F Fei, EJ Joo, SS Tarighat, I Schiffer, H Paz, M Fabbri… - Oncotarget, 2015 - ncbi.nlm.nih.gov
The molecular interactions between B-cell precursor acute lymphoblastic leukemia (pre-B
ALL) cells and stromal cells in the bone marrow that provide microenvironmentally-mediated …

Inhibitors of BCR signalling interrupt the survival signal mediated by the micro‐environment in mantle cell lymphoma

S Bernard, D Danglade, L Gardano… - … journal of cancer, 2015 - Wiley Online Library
Several studies provide evidences for mantle cell lymphoma (MCL) cell survival relying on B‐
cell receptor (BCR)‐mediated signalling pathways, whereas the nature of this activation is …

Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells

Q Kang, S Yan - Experimental and therapeutic …, 2015 - spandidos-publications.com
Drug resistance is an important obstacle to human leukemia therapeutics. Piperlongumine
has previously demonstrated the ability to suppress certain human tumor processes; …

Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiation

SC Roode, D Rotroff, AC Avery, SE Suter… - Chromosome …, 2015 - Springer
Leukemia in dogs is a heterogeneous disease with survival ranging from days to years,
depending on the subtype. Strides have been made in both human and canine leukemia to …

[HTML][HTML] Krüppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of …

K Filarsky, A Garding, N Becker, C Wolf… - …, 2016 - ncbi.nlm.nih.gov
The pathomechanism of chronic lymphocytic leukemia (CLL) is an interplay of genomic and
epigenomic aberrations. Next generation sequencing (NGS) identified mutations in CLL that …

Inflammation as a driver of hematological malignancies

S Saluja, I Bansal, R Bhardwaj, MS Beg… - Frontiers in …, 2024 - frontiersin.org
Hematopoiesis is a tightly regulated process that produces all adult blood cells and immune
cells from multipotent hematopoietic stem cells (HSCs). HSCs usually remain quiescent, and …

[HTML][HTML] Chronic lymphocytic leukemia–like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic …

G Blanco, A Puiggros, B Sherry, L Nonell, X Calvo… - Experimental …, 2021 - Elsevier
Several studies in chronic lymphocytic leukemia (CLL) patients have reported impaired
immune cell functions, which contribute to tumor evasion and disease progression …

Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types?

JR Slupsky - Scientifica, 2014 - Wiley Online Library
Chronic lymphocytic leukaemia (CLL) is an incurable malignancy of mature B cells. CLL is
important clinically in Western countries because of its commonality and because of the …